Redhill Biopharma Ltd. (NASDAQ:RDHL) Stock Short Interest Falls 39.2%

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 128,328 shares, a decrease of 39.2% from the September 30th total of 211,200 shares. Based on an average daily trading volume, of 1,568,822 shares, the short-interest ratio is presently 0.1 days. Approximately 1.5% of the company’s stock are short sold.

Redhill Biopharma Stock Performance

Shares of RDHL stock traded up $0.05 on Monday, hitting $0.44. 313,228 shares of the stock traded hands, compared to its average volume of 839,197. The company’s fifty day moving average is $0.56 and its 200 day moving average is $0.81. Redhill Biopharma has a 1-year low of $0.38 and a 1-year high of $1.60.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious diseases. The company was founded in Israel and later operated as a publicly traded company in the United States under the ticker symbol RDHL.

RedHill’s principal commercial product was Talicia, an oral combination of omeprazole, amoxicillin and rifabutin approved by the U.S. Food and Drug Administration for the treatment of Helicobacter pylori infection in adults.